We approach the future of digital nose diagnostics with a “medtech first” mentality. One built around healthcare expertise, regulatory strategy, and groundbreaking technologies. Our solutions arise from rethinking technology from the ground up to solve unmet needs.
Innovation is more than adapting sensor technologies, we need to transform them.
Research clearly indicates the potential of VOCs for health diagnostics, but the market lacks a low-cost, scalable, highly miniaturized sensor to enable real-world use.
Until now. Until Ainos.
Replicating the human nose through technology is a true challenge. With hundreds of smell receptors and the ability to distinguish trillions of scents, the human nose has been an integral part of disease identification for centuries. It is a powerful, rapid, and non-invasive tool of detection.
And Ainos is harnessing that acumen for modern medicine.
Volatile organic compounds (VOCs) are found throughout the human body, these gaseous molecules originate:
• Naturally from our body (e.g. from the metabolic system)
• As a result of bacteria or infection
• from environmental factors (e.g. from pollutants or diet)
Studies have identified hundreds of VOCs emitted from the human body via breath, sweat, skin, and other bodily secretions.
Stored inside the VOC molecules are an incredible wealth of information. Information used to identify disease progression, drug efficacity, or genetic disorders.
As more biomarkers are uncovered in VOCs, we can rapidly develop non-invasive methods of early disease, infection, or cancer detection.
Methods that allow for quick and confident prognosis.
Methods that when combine with doctors’ experience allows for less ambiguity and better patient outcomes.
Methods that save lives.
VOCs can help us quickly identify these…
Securing these molecules is just the first step. Unlocking their secrets is the next.
Our “medtech first” mentality developed CHS430, a device that rapidly detects ventilator-associated pneumonia (VAP) in 10 minutes. Unlocking the information in breath biomarkers, in real time, provided doctors the critical information they need to provide better outcomes in high-pressure environments like the ER.
CHS430 represents years of work effectively combining of digital nose sensor arrays along with Ainos’s own bionic algorithm and analysis systems.
CHS430 validated the possibility for digital nose diagnostics in critical care. Ainos took the knowledge gained to widen its focus to POCT (point-of-care-testing). This unlocked a new level of professional and consumer level diagnostics in healthcare.
Ainos didn't want modest upgrades or iterative changes.
We wanted beyond better; we wanted evolution.
Our team rebuilt the technologies behind odor and gas sensors by leveraging Taiwan's unrivaled understanding of semiconductor systems. Through Micro Electro Mechanical Systems (MEMS) processes, Ainos developed its own miniaturized sensor arrays that could gather the complexity of scent data required to make revolutionary advances in healthcare AI.
These sensors were specially designed to adhere to the healthcare standards and regulatory rigor expected by the industry.
To advance telehealth, rapid diagnostics must be available anywhere & anytime.
Ainos has integrated APPs and cloud systems into our products to bring scent diagnostics to the forefront of telehealth.
We want to ensure doctors have real-time health data no matter the location of their patients. Patient’s VOC data is digitized as Smell ID and ready for upload or transmission to a healthcare provider.
The data potential of cloud-based POCT devices is limitless, ensuring strong AIs, and better patient outcomes.